Carfilzomib Regimens Offer a Neuropathy-Sparing Approach in Multiple Myeloma, WM

Share this content:
Carfilzomib-based regimens are well tolerated and offer a neuropathy-sparing approach in newly diagnosed MM and WM.
Carfilzomib-based regimens are well tolerated and offer a neuropathy-sparing approach in newly diagnosed MM and WM.

Frontline carfilzomib-based treatment regimens were well tolerated and effective in patients diagnosed with multiple myeloma (MM) or Waldenström macroglobulinemia (WM), according to a retrospective, single-center study.1

Consistent with prior studies of carfilzomib, and in contrast to bortezomib-based regimens, the study showed that treatment with carfilzomib was tied to low rates of peripheral neuropathy in patients.

“Our data suggest that carfilzomib-based regimens are well tolerated and offer a neuropathy-sparing approach with excellent responses in newly diagnosed MM and WM making them a good choice for frontline treatment of these diseases,” researchers wrote.

The study looked at efficacy and safety of frontline carfilzomib-based regimens in 54 patients with newly diagnosed myeloma and 6 patients with WM treated between 2014 and 2016 at The University of Texas MD Anderson Cancer Center, Houston.

Patients with myeloma were treated with either KRd (carfilzomib, lenalidomide, and dexamethasone) or KCd (carfilzomib, cyclophosphamide, and dexamethasone). Patients with WM were treated with carfilzomib, with dexamethasone and rituximab.

There was a 98% response rate for patients with myeloma with 77% of patients undergoing upfront autologous stem cell transplant. After transplant, responses deepened with 58% of patients achieving complete response, 29% achieving very good partial response, and 13% achieving partial response.  At a median follow-up of 7.4 months, overall survival was 100%. Five patients had to discontinue therapy due to toxicity, including 1 patient with neuropathy.

All patients with WM had clinical benefit and resolution of B symptoms and anemia after treatment. The major response rate was 67%. At a median follow-up of 33.5 months, overall survival was 100%. One patient with WM had severe toxicity: debilitating neuropathy, which was attributed to treatment with rituximab.


  1. Chaudry M, Steiner R, Claussen C, et al. Carfilzomib-based combination regimens are highly effective frontline therapies for multiple myeloma and Waldenström's macroglobulinemia. Leuk Lymphoma. 2018;130(Suppl 1):1880.

Related Resources

You must be a registered member of Cancer Therapy Advisor to post a comment.

Sign Up for Free e-newsletters

Regimen and Drug Listings


Bone Cancer Regimens Drugs
Brain Cancer Regimens Drugs
Breast Cancer Regimens Drugs
Endocrine Cancer Regimens Drugs
Gastrointestinal Cancer Regimens Drugs
Gynecologic Cancer Regimens Drugs
Head and Neck Cancer Regimens Drugs
Hematologic Cancer Regimens Drugs
Lung Cancer Regimens Drugs
Other Cancers Regimens
Prostate Cancer Regimens Drugs
Rare Cancers Regimens
Renal Cell Carcinoma Regimens Drugs
Skin Cancer Regimens Drugs
Urologic Cancers Regimens Drugs